KR20100041849A - Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도 - Google Patents

Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도 Download PDF

Info

Publication number
KR20100041849A
KR20100041849A KR1020107003921A KR20107003921A KR20100041849A KR 20100041849 A KR20100041849 A KR 20100041849A KR 1020107003921 A KR1020107003921 A KR 1020107003921A KR 20107003921 A KR20107003921 A KR 20107003921A KR 20100041849 A KR20100041849 A KR 20100041849A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107003921A
Other languages
English (en)
Korean (ko)
Inventor
러셀 피. 로데르
수잔 파스 맥나이트
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Publication of KR20100041849A publication Critical patent/KR20100041849A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020107003921A 2007-07-25 2008-07-25 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도 Abandoned KR20100041849A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
US60/962,022 2007-07-25

Publications (1)

Publication Number Publication Date
KR20100041849A true KR20100041849A (ko) 2010-04-22

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107003921A Abandoned KR20100041849A (ko) 2007-07-25 2008-07-25 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도

Country Status (9)

Country Link
US (3) US8252285B2 (https=)
EP (1) EP2178561A1 (https=)
JP (4) JP2010534243A (https=)
KR (1) KR20100041849A (https=)
AU (1) AU2008279619B2 (https=)
BR (1) BRPI0814644A2 (https=)
CA (1) CA2697159C (https=)
MX (1) MX2010000981A (https=)
WO (1) WO2009014745A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018199378A1 (ko) * 2017-04-27 2018-11-01 서울대학교 산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252285B2 (en) 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AU2012212066A1 (en) * 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US12414983B2 (en) 2019-01-14 2025-09-16 Regents Of The University Of Minnesota CD200AR ligands for cancer immunotherapy
EP4296280A1 (en) 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
MXPA05006978A (es) 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
WO2009014744A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Methods and compositions for treating autoimmune disease
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018199378A1 (ko) * 2017-04-27 2018-11-01 서울대학교 산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법

Also Published As

Publication number Publication date
CA2697159C (en) 2017-02-14
AU2008279619B2 (en) 2013-11-14
EP2178561A1 (en) 2010-04-28
JP2013163695A (ja) 2013-08-22
US20100291085A1 (en) 2010-11-18
USRE46323E1 (en) 2017-02-28
BRPI0814644A2 (pt) 2015-01-27
WO2009014745A1 (en) 2009-01-29
CA2697159A1 (en) 2009-01-29
JP2016117762A (ja) 2016-06-30
US8252285B2 (en) 2012-08-28
US8637014B2 (en) 2014-01-28
US20120321625A1 (en) 2012-12-20
JP2010534243A (ja) 2010-11-04
AU2008279619A1 (en) 2009-01-29
JP5926702B2 (ja) 2016-05-25
MX2010000981A (es) 2010-05-21
JP2015172090A (ja) 2015-10-01

Similar Documents

Publication Publication Date Title
KR20100041849A (ko) Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도
DK2463305T3 (en) Antibodies to OX-2 / CD200 and uses thereof
KR101601387B1 (ko) c-KIT 항체 및 이의 용도
TWI855499B (zh) 嵌合受體和使用彼之方法
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
AU2015292406B2 (en) Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
CN106715471B (zh) 抗cd127的抗体
JP2024045121A (ja) 抗ｃｄ３８抗体の皮下投薬
KR20100097684A (ko) Ａｘｌ 항체
JP2025106512A (ja) 調節性ｔ細胞及びその使用
KR20180030899A (ko) Pd-l1 (“프로그램화된 사멸-리간드 1”) 항체
KR20140066259A (ko) 항-ｃｄ３８ 인간 항체 및 그의 용도
KR20210031694A (ko) 엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법
US20210069246A1 (en) Combination therapy using adoptive cell therapy and checkpoint inhibitor
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
CN114786723A (zh) 序贯抗cd19疗法
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
KR20220088425A (ko) 항 garp 항체와 면역 조절제의 조합
WO2021091815A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
AU2014200678A1 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses
IL322506A (en) Combinations of BTN3A activating antibody and immune checkpoint inhibitors
TW202045547A (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130412

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140822

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150310

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee